RT Journal Article
T1 Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
A1 Oliver, Jaime Antonio
A1 Ortiz, Raúl
A1 Melguizo, Consolación
A1 Álvarez, Pablo Juan
A1 Gómez-Millán, Jaime
A1 Prados, José
K1 Colorectal cancer
K1 MGMT
K1 CD133
K1 Methylation status
K1 Biomarker
K1 Overall survival
K1 Disease free-survival
K1 Neoplasias colorrectales
K1 Marcadores biológicos de tumor
K1 Metilación de ADN
K1 Pronóstico
K1 Regiones promotoras genéticas
K1 Supervivencia sin enfermedad
K1 Enzimas reparadoras del ADN
AB BACKGROUNDNew biomarkers are needed for the prognosis of advanced colorectal cancer, which remains incurable by conventional treatments. O6-methylguanine DNA methyltransferase (MGMT) methylation and protein expression have been related to colorectal cancer treatment failure and tumor progression. Moreover, the presence in these tumors of cancer stem cells, which are characterized by CD133 expression, has been associated with chemoresistance, radioresistance, metastasis, and local recurrence. The objective of this study was to determine the prognostic value of CD133 and MGMT and their possible interaction in colorectal cancer patients.METHODSMGMT and CD133 expression was analyzed by immunohistochemistry in 123 paraffin-embedded colorectal adenocarcinoma samples, obtaining the percentage staining and intensity. MGMT promoter methylation status was obtained by using bisulfite modification and methylation-specific PCR (MSP). These values were correlated with clinical data, including overall survival (OS), disease-free survival (DFS), tumor stage, and differentiation grade.RESULTSLow MGMT expression intensity was significantly correlated with shorter OS and was a prognostic factor independently of treatment and histopathological variables. High percentage of CD133 expression was significantly correlated with shorter DFS but was not an independent factor. Patients with low-intensity MGMT expression and ≥50% CD133 expression had the poorest DFS and OS outcomes.CONCLUSIONSOur results support the hypothesis that MGMT expression may be an OS biomarker as useful as tumor stage or differentiation grade and that CD133 expression may be a predictive biomarker of DFS. Thus, MGMT and CD133 may both be useful for determining the prognosis of colorectal cancer patients and to identify those requiring more aggressive adjuvant therapies. Future studies will be necessary to determine its clinical utility.
PB BioMed Central
YR 2014
FD 2014-07-11
LK http://hdl.handle.net/10668/1807
UL http://hdl.handle.net/10668/1807
LA en
NO Oliver JA, Ortiz R, Melguizo C, Alvarez PJ, Gómez-Millán J, Prados J. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer. 2014; 14(1):511
NO Journal Article;
DS RISalud
RD Apr 6, 2025